About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Coeptis Anchors $800M Valuation in Dual-Sector Strategy; Vanderbilt Report Publishes Coverage

BRISTOL, TN / ACCESS Newswire / October 1, 2025 / Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) today announced that The Vanderbilt Report has published coverage of the company following its recent SEC filings.

According to disclosures filed on January 31, 2025, Coeptis' technology division was assigned a $660.3 million fair market value. In addition, management has outlined a planned biotech spin-out, valued at approximately $75 million, together with tax advantages that may support future profitability.

The Vanderbilt Report reviewed these filings and highlighted a combined valuation framework of approximately $835 million, marking a milestone in Coeptis' transition from a pure biopharmaceutical operator to a dual-sector enterprise spanning both life sciences and advanced technology.

Why This Matters:

  • Credible Benchmark: The $660M valuation stems directly from Coeptis' SEC disclosures.

  • Biotech Spin-Out: Management intends to distribute oncology and cell therapy programs on a 1:1 basis to shareholders, with a proposed uplisting to Nasdaq.

  • Independent Coverage: Vanderbilt Report has published analysis of these disclosures, underscoring the significance of the dual-sector model..

Read the full Vanderbilt Report analysis here

About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company.

The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis' therapeutic portfolio includes assets licensed from Deverra Therapeutics, such as an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Coeptis is also developing SNAP-CAR, a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, alongside its GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and researchers at the Karolinska Institute.

Building on its core competencies, Coeptis has recently established a Technology Division, which includes AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group. These technologies are designed to optimize operations and enhance overall efficiency.

Headquartered in Wexford, PA, Coeptis is committed to advancing patient outcomes through innovation while operating under the highest standards of compliance and regulatory oversight. For more information, visit https://coeptistx.com.

Compliance Note: This announcement is based on Coeptis Therapeutics' SEC filings (10-Q, S-4, valuation disclosures) and public information. It does not constitute investment advice, a solicitation, or a recommendation to buy or sell securities.

CONTACT
Vanderbilt Report Media Relations
Kristen Owens
info@vanderbiltreport.com

SOURCE: Coeptis Therapeutics



View the original press release on ACCESS Newswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.